Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
暂无分享,去创建一个
Arndt Borkhardt | Christina Peters | A. Borkhardt | M. Schrappe | C. Eckert | G. Henze | K. Seeger | R. Panzer‐Grümayer | G. Escherich | T. Klingebiel | C. Peters | G. Mann | A. Schrauder | A. von Stackelberg | F. Niggli | Georg Mann | Martin Schrappe | Thomas Klingebiel | Günter Henze | André Schrauder | Arend von Stackelberg | Cornelia Eckert | Renate Panzer-Grümayer | L. Sramkova | Felix Niggli | J. Hitzler | Karlheinz Seeger | Nikola Hagedorn | Gabriele Escherich | Lucie Sramkova | Johann Hitzler | N. Hagedorn | R. Panzer-Grümayer
[1] S. Hunger,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.
[2] Douglas G Altman,et al. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.
[3] J. V. van Dongen,et al. Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. , 2004, Blood.
[4] J. V. van Dongen,et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. , 1999, Blood.
[5] T. Szczepański,et al. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations , 1997, Leukemia.
[6] A. Órfão,et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). , 1998, Blood.
[7] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.
[8] F. Aversa,et al. Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.
[9] Dario Campana,et al. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia , 2012, Current opinion in hematology.
[10] D. Campana,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.
[11] G. Henze,et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. , 1993, Medical and pediatric oncology.
[12] A. Borkhardt,et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. , 2013, European journal of cancer.
[13] J. V. van Dongen,et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.
[14] A. Porwit,et al. Acute leukemias of ambiguous lineage. , 2012, Seminars in diagnostic pathology.
[15] D. Campana. Progress of Minimal Residual Disease Studies in Childhood Acute Leukemia , 2010, Current hematologic malignancy reports.
[16] M. Borowitz,et al. Acute leukaemias of ambiguous lineage. . , 2001 .
[17] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[18] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[19] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[20] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[21] P. Gaynon. Childhood acute lymphoblastic leukaemia and relapse , 2005, British journal of haematology.
[22] C. Eckert,et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia , 2001, The Lancet.
[23] C. Eckert,et al. Real-time PCR to detect minimal residual disease in childhood ALL. , 2004, Methods in molecular medicine.
[24] C. Eckert,et al. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes , 2003, Leukemia.
[25] M. Valsecchi,et al. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia , 2011, British journal of haematology.
[26] D. Campana. Molecular determinants of treatment response in acute lymphoblastic leukemia. , 2008, Hematology. American Society of Hematology. Education Program.
[27] Great,et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial , 2010, The Lancet.
[28] Dario Campana,et al. Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[29] M. Schrappe,et al. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials , 2008, Bone Marrow Transplantation.
[30] G. Henze,et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. , 2003, Blood.
[31] Treatment of Relapsed Acute Lymphoblastic Leukemia , 2003 .
[32] M. Schrappe,et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Hunger,et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.